Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 238

1.

GDP-l-fucose synthase is a CD4+ T cell-specific autoantigen in DRB3*02:02 patients with multiple sclerosis.

Planas R, Santos R, Tomas-Ojer P, Cruciani C, Lutterotti A, Faigle W, Schaeren-Wiemers N, Espejo C, Eixarch H, Pinilla C, Martin R, Sospedra M.

Sci Transl Med. 2018 Oct 10;10(462). pii: eaat4301. doi: 10.1126/scitranslmed.aat4301.

PMID:
30305453
2.

Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis.

Jelcic I, Al Nimer F, Wang J, Lentsch V, Planas R, Jelcic I, Madjovski A, Ruhrmann S, Faigle W, Frauenknecht K, Pinilla C, Santos R, Hammer C, Ortiz Y, Opitz L, Grönlund H, Rogler G, Boyman O, Reynolds R, Lutterotti A, Khademi M, Olsson T, Piehl F, Sospedra M, Martin R.

Cell. 2018 Sep 20;175(1):85-100.e23. doi: 10.1016/j.cell.2018.08.011. Epub 2018 Aug 30.

3.

Detailed Characterization of T Cell Receptor Repertoires in Multiple Sclerosis Brain Lesions.

Planas R, Metz I, Martin R, Sospedra M.

Front Immunol. 2018 Mar 19;9:509. doi: 10.3389/fimmu.2018.00509. eCollection 2018.

4.

CD5L is upregulated in hepatocellular carcinoma and promotes liver cancer cell proliferation and antiapoptotic responses by binding to HSPA5 (GRP78).

Aran G, Sanjurjo L, Bárcena C, Simon-Coma M, Téllez É, Vázquez-Vitali M, Garrido M, Guerra L, Díaz E, Ojanguren I, Elortza F, Planas R, Sala M, Armengol C, Sarrias MR.

FASEB J. 2018 Jul;32(7):3878-3891. doi: 10.1096/fj.201700941RR. Epub 2018 Feb 20.

PMID:
29465313
5.

High Prevalence of Liver Fibrosis Among European Adults With Unknown Liver Disease: A Population-Based Study.

Caballería L, Pera G, Arteaga I, Rodríguez L, Alumà A, Morillas RM, de la Ossa N, Díaz A, Expósito C, Miranda D, Sánchez C, Prats RM, Urquizu M, Salgado A, Alemany M, Martinez A, Majeed I, Fabrellas N, Graupera I, Planas R, Ojanguren I, Serra M, Torán P, Caballería J, Ginès P.

Clin Gastroenterol Hepatol. 2018 Jul;16(7):1138-1145.e5. doi: 10.1016/j.cgh.2017.12.048. Epub 2018 Feb 13.

6.

HEPACONTROL. A program that reduces early readmissions, mortality at 60 days, and healthcare costs in decompensated cirrhosis.

Morales BP, Planas R, Bartoli R, Morillas RM, Sala M, Casas I, Armengol C, Masnou H.

Dig Liver Dis. 2018 Jan;50(1):76-83. doi: 10.1016/j.dld.2017.08.024. Epub 2017 Aug 13.

PMID:
28870446
7.

Neurological manifestations of excessive alcohol consumption.

Planas-Ballvé A, Grau-López L, Morillas RM, Planas R.

Gastroenterol Hepatol. 2017 Dec;40(10):709-717. doi: 10.1016/j.gastrohep.2017.05.011. Epub 2017 Jun 24. Review. English, Spanish.

PMID:
28651796
8.

Early hospital readmission in decompensated cirrhosis: Incidence, impact on mortality, and predictive factors.

Morales BP, Planas R, Bartoli R, Morillas RM, Sala M, Cabré E, Casas I, Masnou H.

Dig Liver Dis. 2017 Aug;49(8):903-909. doi: 10.1016/j.dld.2017.03.005. Epub 2017 Mar 18.

PMID:
28410915
9.

Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease.

Hézode C, Almasio PL, Bourgeois S, Buggisch P, Brown A, Diago M, Horsmans Y, Serfaty L, Szalay F, Gaeta GB, Planas R, Schlag M, Lonjon-Domanec I, Omoruyi E, DeMasi R, Zeuzem S.

Liver Int. 2017 Sep;37(9):1304-1313. doi: 10.1111/liv.13376. Epub 2017 Mar 13.

PMID:
28135777
10.

Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO).

Buti M, Calleja JL, Lens S, Diago M, Ortega E, Crespo J, Planas R, Romero-Gómez M, Rodríguez FG, Pascasio JM, Fevery B, Kurland D, Corbett C, Kalmeijer R, Jessner W.

Aliment Pharmacol Ther. 2017 Feb;45(3):468-475. doi: 10.1111/apt.13883. Epub 2016 Nov 29.

11.

Depression as Measured by PHQ-9 Versus Clinical Diagnosis as an Independent Predictor of Long-Term Mortality in a Prospective Cohort of Medical Inpatients.

Martin-Subero M, Kroenke K, Diez-Quevedo C, Rangil T, de Antonio M, Morillas RM, Lorán ME, Mateu C, Lupon J, Planas R, Navarro R.

Psychosom Med. 2017 Apr;79(3):273-282. doi: 10.1097/PSY.0000000000000390.

PMID:
27606795
12.

Mechanisms of immune escape in central nervous system infection with neurotropic JC virus variant.

Jelcic I, Jelcic I, Kempf C, Largey F, Planas R, Schippling S, Budka H, Sospedra M, Martin R.

Ann Neurol. 2016 Mar;79(3):404-18. doi: 10.1002/ana.24574. Epub 2016 Feb 13.

13.

B-cell anergy induces a Th17 shift in a novel B lymphocyte transgenic NOD mouse model, the 116C-NOD mouse.

Carrascal J, Carrillo J, Arpa B, Egia-Mendikute L, Rosell-Mases E, Pujol-Autonell I, Planas R, Mora C, Mauricio D, Ampudia RM, Vives-Pi M, Verdaguer J.

Eur J Immunol. 2016 Mar;46(3):593-608. doi: 10.1002/eji.201445376. Epub 2016 Jan 12.

14.

Central role of Th2/Tc2 lymphocytes in pattern II multiple sclerosis lesions.

Planas R, Metz I, Ortiz Y, Vilarrasa N, Jelčić I, Salinas-Riester G, Heesen C, Brück W, Martin R, Sospedra M.

Ann Clin Transl Neurol. 2015 Sep;2(9):875-93. doi: 10.1002/acn3.218. Epub 2015 Jun 8.

15.

[Triple therapy in cirrhotic patients and those with advanced fibrosis: relevant aspects in clinical practice].

Albillos A, Luis Calleja J, Molina E, Planas R, Romero-Gómez M, Turnes J, Hernández-Guerra M.

Gastroenterol Hepatol. 2014 Jul;37 Suppl 1:13-22. doi: 10.1016/S0210-5705(15)30003-0. Review. Spanish.

PMID:
25907434
16.

[Hepatitis C in 2014: responses to frequent questions in daily clinical practice].

Planas R.

Gastroenterol Hepatol. 2014 Jul;37 Suppl 1:1-2. doi: 10.1016/S0210-5705(15)30001-7. Spanish. No abstract available.

PMID:
25907432
17.

Prediction of week 4 virological response in hepatitis C for making decision on triple therapy: the Optim study.

Romero-Gómez M, Turnes J, Ampuero J, Oyagüez I, Cuenca B, Gonzalez-Garcia J, Muñoz-Molina B, Aguilar R, Leal S, Planas R, Garcia-Samaniego J, Diago M, Crespo J, Calleja JL, Casado MA, Sola R.

PLoS One. 2015 Mar 31;10(3):e0122613. doi: 10.1371/journal.pone.0122613. eCollection 2015.

18.

Cost-Effectiveness Analysis Of Triple Therapy With Peginterferon, Ribavirin, And Boceprevir For The Treatment Of Chronic Hepatitis C Virus Genotype 1 With Severe Fibrosis Under "Real-Life" Conditions.

Ruiz-Antorán B, Pascasio JM, Gea F, Barcena R, Larrubia J, Pérez ÁR, Sousa J, Romero GM, Solá R, de lR, Crespo J, Navarro J, Arenas J, Delgado M, Fernández RC, Planas R, Buti M, Forns X, Calleja JL.

Value Health. 2014 Nov;17(7):A367. doi: 10.1016/j.jval.2014.08.822. Epub 2014 Oct 26. No abstract available.

19.

Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1.

Sospedra M, Schippling S, Yousef S, Jelcic I, Bofill-Mas S, Planas R, Stellmann JP, Demina V, Cinque P, Garcea R, Croughs T, Girones R, Martin R.

Clin Infect Dis. 2014 Dec 1;59(11):1588-92. doi: 10.1093/cid/ciu682. Epub 2014 Sep 11.

20.

Adoptive transfer of EBV specific CD8+ T cell clones can transiently control EBV infection in humanized mice.

Antsiferova O, Müller A, Rämer PC, Chijioke O, Chatterjee B, Raykova A, Planas R, Sospedra M, Shumilov A, Tsai MH, Delecluse HJ, Münz C.

PLoS Pathog. 2014 Aug 28;10(8):e1004333. doi: 10.1371/journal.ppat.1004333. eCollection 2014 Aug.

21.

Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis.

Calleja JL, Pascasio JM, Ruiz-Antorán B, Gea F, Bárcena R, Larrubia JR, Pérez-Álvarez R, Sousa JM, Romero-Gómez M, Solá R, de la Revilla J, Crespo J, Navarro JM, Arenas JI, Delgado M, Fernández-Rodríguez CM, Planas R, Buti M, Forns X; Spanish Group for the Study of the Use of Direct-Acting Drugs Hepatitis C with Severe Fibrosis.

Liver Int. 2015 Jan;35(1):90-100. doi: 10.1111/liv.12656. Epub 2014 Sep 15.

PMID:
25113158
22.

[Characterization of patients with chronic hepatitis B virus infection without indication for treatment].

Planas R.

Gastroenterol Hepatol. 2014 Jul;37 Suppl 2:1-4. doi: 10.1016/S0210-5705(14)70061-5. Spanish.

PMID:
25087704
23.

New method for isolation of rat lamina propria macrophages in colonic tissue.

Bargalló A, Abad L, Odena G, Planas R, Bartolí R.

J Immunol Methods. 2014 Jun;408:132-6. doi: 10.1016/j.jim.2014.05.002. Epub 2014 May 9.

PMID:
24816467
24.

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR; PEARL-III Study; PEARL-IV Study.

N Engl J Med. 2014 May 22;370(21):1983-92. doi: 10.1056/NEJMoa1402338. Epub 2014 May 4.

25.

[Non-alcoholic fatty liver: position document of the Catalan Society of Gastroenterology].

Caballería L, Saló J, Berzigotti A, Planas R, Vila C, Huertas C, Torres M, Torán P, Caballería J; Societat Catalana de Digestologia.

Gastroenterol Hepatol. 2014 Jun-Jul;37(6):372-83. doi: 10.1016/j.gastrohep.2014.03.005. Epub 2014 Apr 18. Spanish. No abstract available.

PMID:
24746904
26.

Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life.

Planas R, Martin R, Sospedra M.

Patient Relat Outcome Meas. 2014 Apr 4;5:25-33. doi: 10.2147/PROM.S41768. eCollection 2014. Review.

27.

Tools for the diagnosis of hepatitis C virus infection and hepatic fibrosis staging.

Saludes V, González V, Planas R, Matas L, Ausina V, Martró E.

World J Gastroenterol. 2014 Apr 7;20(13):3431-42. doi: 10.3748/wjg.v20.i13.3431. Review.

28.

[Prevention of hepatic encephalopathy].

Morillas RM, Sala M, Planas R.

Med Clin (Barc). 2014 Jun 6;142(11):512-4. doi: 10.1016/j.medcli.2013.11.027. Epub 2014 Jan 28. Review. Spanish.

PMID:
24480288
29.

Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study.

Fernández-Rodríguez CM, Morillas RM, Masnou H, Navarro JM, Bárcena R, González JM, Martín-Martín L, Poyato A, Miquel-Planas M, Jorquera F, Casanovas T, Salmerón J, Calleja JL, Solà R, Alonso S, Planas R, Romero-Gomez M.

Gastroenterol Hepatol. 2014 Jan;37(1):1-8. doi: 10.1016/j.gastrohep.2013.10.005. Epub 2013 Dec 17.

PMID:
24360571
30.

Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline.

Sanmartín R, Tor J, Sanvisens A, López JJ, Jou A, Muga R, Ojanguren I, Barluenga E, Videla S, Planas R, Clotet B, Tural C.

HIV Med. 2014 Apr;15(4):203-12. doi: 10.1111/hiv.12105. Epub 2013 Nov 19.

31.

Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.

Turnes J, Romero-Gómez M, Planas R, Solà R, García-Samaniego J, Diago M, Crespo J, Calleja JL, Rubio-Terrés C, Ventayol P.

Gastroenterol Hepatol. 2013 Nov;36(9):555-64. doi: 10.1016/j.gastrohep.2013.08.003. Epub 2013 Oct 9.

PMID:
24119723
32.

[Clinical use of telaprevir: stopping rules, predicting response, treatment length, and management of adverse effects].

Tural C, Planas R.

Enferm Infecc Microbiol Clin. 2013 Jul;31 Suppl 3:19-25. doi: 10.1016/S0213-005X(13)70120-4. Review. Spanish.

PMID:
24063899
33.

Relevance of baseline viral genetic heterogeneity and host factors for treatment outcome prediction in hepatitis C virus 1b-infected patients.

Saludes V, Bascuñana E, Jordana-Lluch E, Casanovas S, Ardèvol M, Soler E, Planas R, Ausina V, Martró E.

PLoS One. 2013 Aug 28;8(8):e72600. doi: 10.1371/journal.pone.0072600. eCollection 2013.

34.

Efferocytosis promotes suppressive effects on dendritic cells through prostaglandin E2 production in the context of autoimmunity.

Pujol-Autonell I, Ampudia RM, Planas R, Marin-Gallen S, Carrascal J, Sanchez A, Marin A, Puig-Domingo M, Pujol-Borrell R, Verdaguer J, Vives-Pi M.

PLoS One. 2013 May 15;8(5):e63296. doi: 10.1371/journal.pone.0063296. Print 2013.

35.

Meta-analysis: pegylated interferon α-2a achieves higher early virological responses than α-2b in chronic hepatitis C.

Romero-Gómez M, Planas R, Ampuero J, Solà R, García-Samaniego J, Diago M, Crespo J, Calleja JL, Turnes J.

Aliment Pharmacol Ther. 2013 Jun;37(11):1065-73. doi: 10.1111/apt.12314. Epub 2013 Apr 14.

36.

Biomarkers for diagnosis and monitoring of celiac disease.

Vives-Pi M, Takasawa S, Pujol-Autonell I, Planas R, Cabre E, Ojanguren I, Montraveta M, Santos AL, Ruiz-Ortiz E.

J Clin Gastroenterol. 2013 Apr;47(4):308-13. doi: 10.1097/MCG.0b013e31827874e3. Review.

PMID:
23388848
37.

Urinary levels of regenerating protein Iα do not differentiate celiac patients and healthy subjects.

Ruíz-Ortiz E, Santos AL, Pujol-Autonell I, Planas R, Montraveta M, Pintos G, Doladé M, Cabré E, Vives-Pi M.

Biomarkers. 2013 Mar;18(2):178-80. doi: 10.3109/1354750X.2012.745903. Epub 2013 Jan 11.

PMID:
23312007
38.

T cell epitope mapping of JC polyoma virus-encoded proteome reveals reduced T cell responses in HLA-DRB1*04:01+ donors.

Jelcic I, Aly L, Binder TM, Jelcic I, Bofill-Mas S, Planas R, Demina V, Eiermann TH, Weber T, Girones R, Sospedra M, Martin R.

J Virol. 2013 Mar;87(6):3393-408. doi: 10.1128/JVI.02803-12. Epub 2013 Jan 9.

39.

Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4.

Urquijo JJ, Diago M, Boadas J, Planas R, Solá R, Del Olmo JA, Crespo J, Erdozaín JC, Antón MD, Arocena C, Suarez D, Giné J, Barrera JM, Gracia-Samaniego J, Perez R, Dalmau B, Montoro M.

Ann Hepatol. 2013 Jan-Feb;12(1):30-5.

40.

Evolutionary dynamics of the E1-E2 viral populations during combination therapy in non-responder patients chronically infected with hepatitis C virus subtype 1b.

Saludes V, González-Candelas F, Planas R, Solà R, Ausina V, Martró E.

Infect Genet Evol. 2013 Jan;13:1-10. doi: 10.1016/j.meegid.2012.09.012. Epub 2012 Sep 26.

PMID:
23022712
41.

TCR bias and HLA cross-restriction are strategies of human brain-infiltrating JC virus-specific CD4+ T cells during viral infection.

Yousef S, Planas R, Chakroun K, Hoffmeister-Ullerich S, Binder TM, Eiermann TH, Martin R, Sospedra M.

J Immunol. 2012 Oct 1;189(7):3618-30. Epub 2012 Aug 31.

42.

[Portal hypertension: recommendations for evaluation and treatment: consensus document sponsored by the Spanish Association for the Study of the Liver (AEEH) and the Biomedical Research Network Center for Liver and Digestive Diseases(CIBERehd)].

Bosch J, Abraldes JG, Albillos A, Aracil C, Bañares R, Berzigotti A, Calleja JL, de la Peña J, Escorsell A, García-Pagán JC, Genescà J, Hernández-Guerra M, Ripoll C, Planas R, Villanueva C.

Gastroenterol Hepatol. 2012 Jun-Jul;35(6):421-50. doi: 10.1016/j.gastrohep.2012.02.009. Epub 2012 May 26. Spanish. No abstract available.

PMID:
22633191
43.

Rifaximin, but not growth factor 1, reduces brain edema in cirrhotic rats.

Odena G, Miquel M, Serafín A, Galan A, Morillas R, Planas R, Bartolí R.

World J Gastroenterol. 2012 May 7;18(17):2084-91. doi: 10.3748/wjg.v18.i17.2084.

44.

[Position paper of the Catalan Society of Gastroenterology: treatment of Genotype 1 Chronic Hepatitis C Virus with Triple Therapy].

Bruguera M, Esteban R, Forns X, Planas R, Quer JC, Solà R, Vergara M; Catalan Society of Gastroenterology.

Gastroenterol Hepatol. 2012 Nov;35(9):667-74. doi: 10.1016/j.gastrohep.2012.03.005. Epub 2012 May 3. Spanish. No abstract available.

PMID:
22560187
45.

Acute hepatitis C in Spain: a retrospective study of 131 cases.

Pérez-Álvarez R, García-Samaniego J, Solá R, Pérez-López R, Bárcena R, Planas R, Cañete N, Manzano ML, Gutiérrez ML, Morano L, Rodrigo L.

Rev Esp Enferm Dig. 2012 Feb;104(1):21-8. English, Spanish.

PMID:
22300113
46.

Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis.

Planas R, Jelčić I, Schippling S, Martin R, Sospedra M.

Eur J Immunol. 2012 Mar;42(3):790-8. doi: 10.1002/eji.201142108. Epub 2011 Dec 27.

47.

Regenerating gene Iα is a biomarker for diagnosis and monitoring of celiac disease: a preliminary study.

Planas R, Pujol-Autonell I, Ruiz E, Montraveta M, Cabre E, Lucas-Martin A, Pujol-Borrell R, Martinez-Caceres E, Vives-Pi M.

Transl Res. 2011 Sep;158(3):140-5. doi: 10.1016/j.trsl.2011.04.004. Epub 2011 May 30.

PMID:
21867979
48.

Long-term clinical course of decompensated alcoholic cirrhosis: a prospective study of 165 patients.

Alvarez MA, Cirera I, Solà R, Bargalló A, Morillas RM, Planas R.

J Clin Gastroenterol. 2011 Nov-Dec;45(10):906-11. doi: 10.1097/MCG.0b013e3182284e13.

PMID:
21814145
49.

[Hepatic elastography. Position paper of the Catalan Society of Gastroenterology].

Carrión JA, Navasa M, Buti M, Torras X, Xiol X, Vergara M, Planas R, Solà R, Forns X.

Gastroenterol Hepatol. 2011 Aug-Sep;34(7):504-10. doi: 10.1016/j.gastrohep.2011.05.008. Epub 2011 Jul 23. Spanish.

PMID:
21783282
50.

Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated β-cell death.

Arif S, Moore F, Marks K, Bouckenooghe T, Dayan CM, Planas R, Vives-Pi M, Powrie J, Tree T, Marchetti P, Huang GC, Gurzov EN, Pujol-Borrell R, Eizirik DL, Peakman M.

Diabetes. 2011 Aug;60(8):2112-9. doi: 10.2337/db10-1643. Epub 2011 Jun 9.

Supplemental Content

Loading ...
Support Center